Seite 1 von 86 Ergebnisse
BACKGROUND OF THE INVENTION
Conditions resulting in or from a systemic inflammatory response syndrome (SIRS) are associated with an exaggerated immune response, oxygen free-radical-mediated injury, and tissue perfusion maldistribution. Such conditions include endotoxin shock, septic shock, sepsis,
BACKGROUND OF THE INVENTION
1. Field of the Invention:
The present invention relates to methods and compositions for treating inflammatory diseases.
2. Discussion of the Background:
The release of inflammatory cytokines such as tumor necrosis factor-alpha (TNF.alpha.) by leukocytes is a means by
FIELD OF THE INVENTION
The present invention relates to method for treating inflammatory bowel disease (IBD) that includes administration of an effective amount of an antagonist of A.sub.2B adenosine receptors (ARs).
BACKGROUND OF THE INVENTION
Inflammatory bowel disease (IBD) is a group of
DESCRIPTION
1. Field of the Invention
The present invention relates to a method of treatment of a pulmonary inflammatory reaction with activation of polymorphonuclear white blood cells in a human patient. The invention further relates to use of adenosine for the manufacture of a medicament for such
CROSS REFERENCE TO RELATED APPLICATION
This patent application is a U.S. National Phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/KR2007/001131, filed on Mar. 7, 2007, entitled ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL
TECHNICAL FIELD
The present invention relates to an agent for treating inflammatory diseases such as sepsis and hepatitis, more particularly, to a therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient.
BACKGROUND ART
At present, there has not yet been
FIELD OF THE INVENTION
The present invention relates to methods of preventing airway remodeling and/or pulmonary inflammation using A.sub.2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other
FIELD
This application relates to the use of inhibitors of extracellular adenosine and/or inhibitors of adenosine receptors, such as adenosine receptor antagonists and agents that decrease formation or degrade extracellular adenosine, to enhance an immune response and inflammation, and in some
FIELD
This application relates to the use of inhibitors of extracellular adenosine and/or inhibitors of adenosine receptors, such as adenosine receptor antagonists and agents that decrease formation or degrade extracellular adenosine, to enhance an immune response and inflammation, and in some
FIELD
This application relates to the use of inhibitors of extracellular adenosine and/or inhibitors of adenosine receptors, such as adenosine receptor antagonists and agents that decrease formation or degrade extracellular adenosine, to enhance an immune response and inflammation, and in some
FIELD
This application relates to the use of inhibitors of extracellular adenosine and/or inhibitors of adenosine receptors, such as adenosine receptor antagonists and agents that decrease formation or degrade extracellular adenosine, to enhance an immune response and inflammation, and in some
BACKGROUND OF THE INVENTION
1. Field of the Invention
This patent relates to a composition comprising oligonucleotides (oligos) that are anti-sense to adenosine receptors, and contain low amounts of or no adenosine (A). These agents are suitable for the treatment, among others, of pulmonary diseases
TECHNICAL FIELD
This invention relates to agents that are useful in the treatment of chronic inflammatory diseases, infection, and autoimmune disorders. More particularly, this invention relates to a compound and a method of treatment for monocyte-mediated diseases or disease states (disorders). In
BACKGROUND OF THE INVENTION
The invention relates to receptors, particularly adenosine receptors.
Adenosine modulates a variety of physiological functions by acting through specific cell surface receptors (Williams, 1987, Annu. Rev. Pharmacol Toxicol, 27:315-345; Linden, 1991, FASEB J, 5:2668-2676).
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to water soluble, aryl substituted 4-amino pyrrolo[2,3-d] pyrimidine and pyrazolo[3,4-d] pyrimidine nucleoside analogs having activity as adenosine